AstraZeneca’s immunotherapy drug treads onto Roche’s small-cell lung cancer turf
Data for AstraZeneca's Imfinzi showed an improvement in overall survival and duration of response in patients with first-line extensive-stage small-cell lung cancer. Roche's Tecentriq already has approval in that indication.